Current management of parainfluenza pneumonitis in immunocompromised patients: a review

Clicks: 180
ID: 10264
2012
Current management of parainfluenza pneumonitis in immunocompromised patients: a review Ann R FalseyUniversity of Rochester, Rochester General Hospital, Rochester, NY, USAAbstract: Parainfluenza viruses (PIV) are common respiratory viruses that belong to the Paramyxoviridae family. PIV infection can lead to a wide variety of clinical syndromes ranging from mild upper respiratory illness to severe pneumonia. Severe disease can be seen in elderly or chronically ill persons and may be fatal in persons with compromised immune systems, particularly children with severe combined immunodeficiency disease syndrome and hematopathic stem cell transplant recipients. At present, there are no licensed antiviral agents for the treatment of PIV infection. Aerosolized or systemic ribavirin in combination with intravenous gamma globulin has been reported in small, uncontrolled series and case reports of immunocompromised patients. A number of agents show antiviral activity in vitro and in animals, but none are currently approved for human use.Keywords: parainfluenza virus, antiviral agents, immunocompromised host
Reference Key
falsey2012currentinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ann R Falsey;
Journal Infection and drug resistance
Year 2012
DOI 10.2147/IDR.S25874
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.